Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia.
作者信息
Kim Seon Young, Huh Hee Jin
机构信息
Department of Laboratory Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Department of Laboratory Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.
出版信息
Ann Lab Med. 2023 Jul 1;43(4):323-324. doi: 10.3343/alm.2023.43.4.323. Epub 2023 Feb 24.
Abstract
摘要
相似文献
1
Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia.
Ann Lab Med. 2023 Jul 1;43(4):323-324. doi: 10.3343/alm.2023.43.4.323. Epub 2023 Feb 24.
2
Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Eur J Haematol. 2017 Jan;98(1):26-37. doi: 10.1111/ejh.12780. Epub 2016 Jun 8.
3
Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Br J Haematol. 2022 Jul;198(1):e3-e8. doi: 10.1111/bjh.18143. Epub 2022 Mar 18.
4
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.
Mod Pathol. 2014 Nov;27(11):1438-46. doi: 10.1038/modpathol.2014.57. Epub 2014 Apr 18.
5
Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.
Haematologica. 2019 Feb;104(2):297-304. doi: 10.3324/haematol.2018.203133. Epub 2018 Aug 31.
6
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
Haematologica. 2014 Mar;99(3):465-73. doi: 10.3324/haematol.2013.093765. Epub 2013 Oct 18.
7
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Haematologica. 2019 Feb;104(2):288-296. doi: 10.3324/haematol.2018.194712. Epub 2018 Aug 9.
8
Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
PLoS One. 2019 Oct 28;14(10):e0224097. doi: 10.1371/journal.pone.0224097. eCollection 2019.
9
Serial Analysis and Comparison of Mutation Profiles in Decitabine-treated Myeloid Sarcoma and Subsequent Acute Myeloid Leukemia Using Next-Generation Sequencing.
Ann Lab Med. 2022 Sep 1;42(5):602-605. doi: 10.3343/alm.2022.42.5.602.
10
Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
Surg Pathol Clin. 2019 Sep;12(3):671-686. doi: 10.1016/j.path.2019.03.009. Epub 2019 May 18.
本文引用的文献
1
Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
Ann Lab Med. 2023 Jul 1;43(4):328-336. doi: 10.3343/alm.2023.43.4.328. Epub 2023 Feb 24.
2
Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
Ann Lab Med. 2022 Sep 1;42(5):558-565. doi: 10.3343/alm.2022.42.5.558.
3
Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling.
J Clin Med. 2022 Jan 18;11(3):483. doi: 10.3390/jcm11030483.
4
Application of Next Generation Sequencing in Laboratory Medicine.
Ann Lab Med. 2021 Jan;41(1):25-43. doi: 10.3343/alm.2021.41.1.25. Epub 2020 Aug 25.
5
Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay.
Ann Lab Med. 2020 Jan;40(1):72-75. doi: 10.3343/alm.2020.40.1.72.
6
Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies.
Ann Lab Med. 2019 Nov;39(6):515-523. doi: 10.3343/alm.2019.39.6.515.
7
Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.
J Mol Diagn. 2018 Jul;20(4):389-397. doi: 10.1016/j.jmoldx.2018.03.005. Epub 2018 Apr 22.
8
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with -ITD mutations.
Blood Adv. 2018 Apr 24;2(8):825-831. doi: 10.1182/bloodadvances.2018015925.
9
Limited Utility of Fluorescence In Situ Hybridization for Recurrent Abnormalities in Acute Myeloid Leukemia at Diagnosis and Follow-up.
Am J Clin Pathol. 2018 Mar 29;149(5):418-424. doi: 10.1093/ajcp/aqy002.
10
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12.
Zotero 插件